78 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
regarding the timing and development of Ovid’s product candidate pipeline and achievement of expected near- and long-term milestones; the potential … severity: a multinational cohort survey. Dev Med Child Neurol, 60: 63-72 3) Douglass LM. Conclusions: long-term management of Lennox-Gastaut syndrome
8-K
EX-99.1
h7lgr
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
huwvthf9jvm
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
8-K
EX-99.1
w39g k8tgq7y
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
8-K
EX-99.1
p4rma
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
f1kdj8lc
10 May 22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
8:05am
8-K
EX-99.1
d8otu8
15 Mar 22
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
8:29am